MIM
TSHA icon

Monashee Investment Management’s Taysha Gene Therapies TSHA Stock Holding History

Monashee Investment Management’s Portfolio TSHA Stock Details TSHA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.36M Buy
+200,000
New +$1.18M 2.29% 20
2020
Q4 		– Sell
-60,000
Closed -$1.34M – 320
2020
Q3 		$1.34M Buy
+60,000
New +$1.41M 0.29% 80

Other funds holding TSHA

Avoro Capital Advisors
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
RA Capital Management
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vestal Point Capital
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
RTW Investments
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Monashee Investment Management's TSHA Position: Q2 2026 in Review

Monashee Investment Management opened a new position in Taysha Gene Therapies (TSHA) in Q2 2026: 200,000 shares worth $1.36M. The stake represents 2.29% of the portfolio and ranks #20 among its holdings. This is a return to the name: Monashee Investment Management previously reported a position in TSHA as recently as Q3 2020.

Monashee Investment Management first reported a position in TSHA in Q3 2020 and has held it in 2 quarters since. 208 funds tracked by Wall St. Rank hold TSHA as of Q2 2026.

  • Monashee Investment Management held 200,000 shares of Taysha Gene Therapies worth $1.36M as of Q2 2026.
  • Taysha Gene Therapies was a new Monashee Investment Management position in Q2 2026.
  • Taysha Gene Therapies made up 2.29% of Monashee Investment Management's portfolio in Q2 2026, its #20 holding.
  • Monashee Investment Management first reported a position in Taysha Gene Therapies in Q3 2020 and has held it in 2 quarters since.
  • 208 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q2 2026.

Based on Monashee Investment Management's 13F filing for Q2 2026, filed 13 Aug 2026.